Kaiser Permanente Mid-Atlantic States (KPMAS) is structured as a closed-network HMO system. KPMAS does not publish a public Spravato-specific clinical criteria document — Spravato is administered through KP's medical benefit, not the pharmacy formulary. For most KPMAS members, accessing Spravato means working through Kaiser's own psychiatry team (Mid-Atlantic Permanente Medical Group). For some plan types — including the Out-of-Area PPO and HMO Plus members willing to use limited out-of-network benefits — Lumin Health is a viable option.
Quick self-check by KPMAS plan type — see the plan-by-plan access table below.
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
KPMAS does not publish a Spravato-specific clinical criteria document. The 'four AD trials' figure that appears in third-party summaries is from Kaiser Permanente Northwest, not KPMAS, and KP Northwest's standard is actually three antidepressant trials plus three augmentation therapies. KPMAS administers Spravato through the medical benefit, with criteria managed internally by Mid-Atlantic Permanente Medical Group (MAPMG) psychiatry teams.
What matters far more for a KPMAS member than the clinical criteria is which plan type you have — because that determines whether you can access Lumin Health at all.
| Your KPMAS plan | Can you access Lumin Health for Spravato? | How |
|---|---|---|
| Out-of-Area PPO | Yes, directly | Use OON benefit; precertification still required through KPMAS Behavioral Health Utilization Management; balance-billing risk applies. (Confirm Lumin Health currently accepts KPMAS Out-of-Area PPO claims by calling Lumin Health before scheduling.) |
| Flexible Choice / Triple Option | Yes, via Option 2 or 3 | Option 2: PHCS/MultiPlan or Cigna PPO network — Lumin Health participates in these networks. Option 3: out-of-network with member cost-share. |
| HMO Plus / DHMO Plus | Limited | Members have a 10–15 OON visits/year cap (per KPMAS plan documents). A Spravato induction course exhausts this cap in 4–6 weeks. OON spend doesn't accrue to your in-network out-of-pocket maximum. |
| Signature / Select / FEHB HMO | Unlikely without referral | KPMAS HMO members “should obtain an approved referral from their primary care physician (PCP)” for external psychiatry per Provider Manual Ch. 14 §14.1. KPMAS structurally routes Spravato candidates internally to MAPMG psychiatry first. |
| Medicare Advantage / Maryland Medicaid | No | External provider access not covered. |
Note: Lumin Health delivers Spravato (esketamine) — FDA-approved nasal spray — and intramuscular (IM) ketamine. Lumin Health does not deliver intravenous (IV) ketamine. Kaiser regions that publish IV-ketamine policies (e.g., Kaiser Permanente Washington) classify IV ketamine for depression as experimental/investigational and non-covered.
If your KPMAS HMO plan can't get you to Spravato at Lumin Health, the practical path is open enrollment. Annual open enrollment varies by employer (typically October–November for January 1 effective). Federal employees on KPMAS via FEHB have Open Season each November–December. Mental-health diagnosis is generally not a qualifying life event — you'll need to wait for the annual window. Plan ahead 6–12 months if Spravato is a near-term need.
The KPMAS 2026 FEHB brochure (RI 73-047) does not mention Spravato or esketamine anywhere across its 125 pages. Coverage falls under generic outpatient pharmacotherapy office-visit copays ($10/$20/$30 High/Standard/Prosper) and Section 5(f) specialty-tier drug copays ($100/$150/$200 per 30-day at Plan medical center pharmacy). The brochure's external-provider clause is unambiguous: “Unless you receive prior approval from us, Plan providers must provide or arrange your care. Call our Behavioral Health Access Unit at 866-530-8778 to make arrangements. If we are unable to provide services in our Plan facilities, you may request a referral to a network provider.” Without prior approval or a KPMAS referral, OON care is “All charges” (member pays 100%).
Two Maryland insurance statutes apply when a commercial carrier reviews a Spravato prior authorization:
Step therapy prohibition for non-FDA-approved alternatives. Under Maryland Insurance Article §15-142, a commercial carrier may not require step therapy when (a) the step-therapy drug is not FDA-approved for the condition being treated, or (b) the prescriber documents that a covered drug ordered for the same condition within the past 180 days was clinically effective. For Spravato — FDA-approved specifically for treatment-resistant depression — this means a carrier cannot require trials of drugs not FDA-approved for TRD as a precondition.
Grievance and adverse-decision review. Under Maryland Insurance Article §15-10A-02, commercial carriers must issue a standard adverse-determination decision within 30 working days, an emergency review within 24 hours, and a behavioral-health emergency-admission review within 2 hours. After internal review, members can request external review through the Maryland Insurance Administration: 120-day filing window, 60-day decision (4 business days for emergencies).
Lumin Health's Bethesda, Maryland location serves the Mid-Atlantic region's commercial-insured Spravato candidates. For Kaiser MAS members specifically, Lumin Health has not yet onboarded KPMAS-route Spravato patients (as of May 2026), so we recommend calling 240-348-6090 before scheduling to confirm your specific plan's billability.
For members who proceed via OON benefits or self-pay, Lumin Health handles:
Lumin Health's PA team also manages appeals on your behalf when an initial request is denied.
Spravato treatment at Lumin Health in the Maryland/DMV area is available at our Bethesda location, which serves patients from across Maryland, the District of Columbia, and Northern Virginia. The Bethesda location is REMS-certified per FDA requirements.
How Kaiser MAS compares with other major Maryland commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
No. KPMAS does not publish a public Spravato-specific clinical criteria document. The ‘four antidepressant trials’ figure that appears in third-party summaries is from Kaiser Permanente Northwest, not KPMAS, and KP Northwest's standard is technically three antidepressant trials plus three augmentation therapies. KPMAS administers Spravato through the medical benefit, with criteria managed internally by MAPMG psychiatry teams.
In principle, an HMO member can receive Spravato at Lumin Health if their primary care physician issues an approved out-of-network referral. In practice, KPMAS structurally routes Spravato candidates to MAPMG psychiatry first, and PCP referrals to external Spravato providers are uncommon. For HMO members, the practical paths are: (1) wait for open enrollment to switch to a non-Kaiser plan; (2) use the limited OON benefit (HMO Plus only, ~10–15 visits/year cap); or (3) self-pay with Spravato withMe assistance.
Lumin Health has not yet onboarded a KPMAS-route Spravato patient as of May 2026. We can support KPMAS Out-of-Area PPO members directly, and KPMAS Flexible Choice members through PHCS/MultiPlan or Cigna PPO network access. Other KPMAS plan types require either a PCP referral or an out-of-pocket pathway. Confirm Lumin Health currently accepts KPMAS Out-of-Area PPO claims by calling Lumin Health before scheduling.
Janssen's Spravato withMe program has two parts: a Savings Program (covers medicine cost) and an Observation Rebate Program (covers session/observation cost). For commercial-insured Kaiser MAS members in Maryland, both programs are valid — combined effective cost is approximately $10/session. Both programs work via rebate-with-EOB for out-of-network situations: the patient pays the provider, gets an EOB from KPMAS, and submits a Rebate Request Form + EOB to Spravato withMe within 365 days. Provider can submit on the patient's behalf with an Assignment-of-Benefits form (call 855-872-1776). Note: Spravato withMe excludes Medicare, Medicaid, TRICARE, VA, and DoD members. SaveOnSP-partnered plans are ineligible. Annual program caps apply — call 844-4S-WITHME for current limits.
Annual open enrollment is the practical window. For employer-sponsored plans, this is usually October–November for January 1 effective. For Federal Employees Health Benefits members on KPMAS, Open Season is November–December. Mental-health diagnosis is generally not a qualifying life event — plan 6–12 months ahead if Spravato is a near-term clinical need. If your employer offers a non-Kaiser PPO option (or KPMAS's own Out-of-Area PPO), that's typically the simplest switch.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from receipt of the denial notice (per Kaiser: "Your appeal must be filed in writing within 180 calendar days of your receipt of our denial letter. The 180 days count starting 5 business days from the date of the notice to allow for mail delivery time, unless you can prove that you received the notice after that 5-business day period."). The 5-business-day mail-delivery construction is unusual — most other payers count from the date of the notice itself. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Kaiser Foundation Health Plan, Member Relations - Appeals, Nine Piedmont Center, 3495 Piedmont Road NE, Atlanta, GA 30305-1736. Phone: 888-225-7202 (appeals discussion line) or 800-777-7902 (Member Services; TTY 711). For Spravato-specific routing: KPMAS Behavioral Health Utilization Management 301-552-1212 (fax 855-414-1703).
Step 2 — Peer-to-peer (P2P) review. Kaiser Permanente operates a closed integrated delivery system — for Kaiser members seeing Kaiser-employed clinicians, peer-to-peer is conducted within Permanente Medical Group rather than through external escalation. For Lumin Health (an out-of-network provider to Kaiser MAS), the appeal context is fundamentally different: denials of Spravato at Lumin Health are typically benefits-based (no out-of-network coverage on your specific plan type) rather than medical-necessity-based. The appeal argument changes accordingly.
Step 3 — Expedited (urgent) appeal. Kaiser must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Call 800-777-7902 (TTY 711) and explicitly request expedited review with documented medical urgency.
Appeal levels. Kaiser MAS provides multiple internal appeal levels with a standard 30-day timeline at each level. Specific level structure depends on your plan type (Out-of-Area PPO, Flexible Choice, HMO Plus, Signature/Select HMO, FEHB).
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Kaiser MAS does not vendor behavioral-health appeals to a separate company — appeals are handled internally by KPMAS Member Relations. For Lumin Health Spravato cases specifically, set realistic expectations: Kaiser HMO members typically lack out-of-network behavioral-health coverage outside Kaiser facilities, so an appeal at Lumin Health usually argues either (a) medical necessity for an out-of-network exception or (b) plan-type-specific OON allowance (e.g., Out-of-Area PPO). The likelihood of overturning a benefits-based denial is materially lower than overturning a medical-necessity denial. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Kaiser Permanente Mid-Atlantic medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 calendar days from receipt of the denial notice (per Kaiser: "Your appeal must be filed in writing within 180 calendar days of your receipt of our denial letter. The 180 days count starting 5 business days from the date of the notice to allow for mail delivery time, unless you can prove that you received the notice after that 5-business day period."). The 5-business-day mail-delivery construction is unusual — most other payers count from the date of the notice itself. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: Kaiser Foundation Health Plan, Member Relations - Appeals, Nine Piedmont Center, 3495 Piedmont Road NE, Atlanta, GA 30305-1736. Phone: 888-225-7202 (appeals discussion line) or 800-777-7902 (Member Services; TTY 711). For Spravato-specific routing: KPMAS Behavioral Health Utilization Management 301-552-1212 (fax 855-414-1703).
Step 2 — Peer-to-peer (P2P) review. Kaiser Permanente operates a closed integrated delivery system — for Kaiser members seeing Kaiser-employed clinicians, peer-to-peer is conducted within Permanente Medical Group rather than through external escalation. For Lumin Health (an out-of-network provider to Kaiser MAS), the appeal context is fundamentally different: denials of Spravato at Lumin Health are typically benefits-based (no out-of-network coverage on your specific plan type) rather than medical-necessity-based. The appeal argument changes accordingly.
Step 3 — Expedited (urgent) appeal. Kaiser must resolve expedited (urgent) appeals within 72 hours when delay jeopardizes the member's health. Call 800-777-7902 (TTY 711) and explicitly request expedited review with documented medical urgency.
Appeal levels. Kaiser MAS provides multiple internal appeal levels with a standard 30-day timeline at each level. Specific level structure depends on your plan type (Out-of-Area PPO, Flexible Choice, HMO Plus, Signature/Select HMO, FEHB).
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. Kaiser MAS does not vendor behavioral-health appeals to a separate company — appeals are handled internally by KPMAS Member Relations. For Lumin Health Spravato cases specifically, set realistic expectations: Kaiser HMO members typically lack out-of-network behavioral-health coverage outside Kaiser facilities, so an appeal at Lumin Health usually argues either (a) medical necessity for an out-of-network exception or (b) plan-type-specific OON allowance (e.g., Out-of-Area PPO). The likelihood of overturning a benefits-based denial is materially lower than overturning a medical-necessity denial. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the Kaiser Permanente Mid-Atlantic medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
